The eMDR account isn't automatic

A device company’s first clearance arrives, the complaint-handling procedure gets written under 21 CFR 803.17, and reporting feels covered — the firm is registered, the device is listed, the SOP cites the right part. None of that creates the one thing an actual Medical Device Report needs in order to leave the building: an account FDA will accept a file from.

The mandate is older than most people’s SOPs

21 CFR 803.12(a) has required manufacturers and importers to submit individual adverse event reports — initial, supplemental, and followup — in an electronic format FDA can process, review, and archive since a final rule published at 79 FR 8832 took effect on August 14, 2015, eighteen months after FDA finalized it. The mandate reaches manufacturers and importers specifically; user facilities are encouraged to file electronically but not required to. A firm that can show electronic filing is not feasible for it may ask FDA for an exemption or variance under 21 CFR 803.19 — in writing, stating how long the exemption is needed — and FDA may grant, modify, or revoke it. Absent that letter, electronic is not an option. It is the only format the rule recognizes.

What “electronic” actually requires you to build

Nothing in 803.12(a) tells a sponsor how to get a file to FDA; that instruction sits one subpart later, in 21 CFR 803.23, pointing outward to FDA’s own electronic-submission guidance. In practice, two routes exist, and both start the same way. A low-volume reporter typically uses eSubmitter, FDA’s free desktop tool, to build a MedWatch 3500A file and submit it through the FDA Electronic Submissions Gateway’s WebTrader interface. A high-volume reporter instead transmits structured HL7 ICSR files over the gateway’s AS2 channel, usually through commercial eMDR software built for that format. Either way, FDA’s own enrollment process runs the same sequence first: a pre-production WebTrader account, a guidance-compliant test submission sent and acknowledged, and only then an email to FDA’s eMDR Helpdesk requesting the production account that actually accepts a real report. Nothing in that sequence is instantaneous, and none of it happens unless someone starts it.

The step registration doesn’t do for you

21 CFR Part 807 establishment registration and device listing is a separate system, built for a different purpose: it tells FDA who you are and what you make. Nothing in 807.20’s registration duty, and nothing in a 510(k) clearance letter, enrolls a firm in the Electronic Submissions Gateway or issues it a submitter account. The two systems don’t share a signup page, a login, or an approval queue — a firm can be fully registered, fully listed, and still have no way to file the one report Part 803 exists to collect.

The practice

The sequencing risk here is self-inflicted and avoidable: build the ESG account and run the test submission while writing the 803.17 procedure that is supposed to govern reporting, not after the first malfunction complaint starts a thirty-day clock. Decide which of the two filing routes matches your expected report volume before you need an answer, and keep the acknowledgment from your test submission on file as evidence the account was live before it had to be. What FDA actually requires, and the sequence its own enrollment process runs a firm through, is public and verifiable, exactly as described above; whether your team is ready for its first reportable event is a question for your own regulatory and quality function to answer on your own facts — this is regulatory intelligence about how the mechanism works, never a substitute for that judgment.